Literature DB >> 8741797

Viruses and human cancers: challenges for preventive strategies.

G de The1.   

Abstract

Virus-associated human cancers provide unique opportunities for preventive strategies. The role of human papilloma viruses (HPV 16 and 18), hepatitis B virus (HBV), Epstein-Barr herpes virus (EBV), and retroviruses (human immunodeficiency virus [HIV] and human T-cell leukemia/lymphoma virus [HTLV]) in the development of common carcinomas and lymphomas represents a major cancer threat, particularly among individuals residing in developing countries, which account for 80% of the world's population. Even though these viruses are not the sole etiological agents of these cancers (as would be the case for infectious diseases), different approaches can be implemented to significantly decrease the incidence of virus-associated malignancies. The first approach is vaccination, which is available for HBV and possibly soon for EBV. The long delay between primary viral infection and development of associated tumors as well as the cost involved with administering vaccinations detracts from the feasibility of such an approach within developing countries. The second approach is to increase efforts to detect pre-cancerous lesions or early tumors using immunovirological means. This would allow early diagnosis and better treatment. The third strategy is linked to the existence of disease susceptibility genes, and suggests that counseling be provided for individuals carrying these genes to encourage them to modify their lifestyles and other conditions associated with increased cancer risks (predictive oncology). Specific recommendations include: a) increase international studies that explore the causes of the large variations in prevalence of common cancers throughout the world; b) conduct interdisciplinary studies involving laboratory investigation and social sciences, which may suggest hypotheses that may then be tested experimentally; and c) promote more preventive and health enhancement strategies in addition to curative and replacement therapies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8741797      PMCID: PMC1518983          DOI: 10.1289/ehp.95103s8269

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  11 in total

1.  Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups.

Authors:  W Henle; G Henle; H C Ho; P Burtin; Y Cachin; P Clifford; A de Schryver; G de-Thé; V Diehl; G Klein
Journal:  J Natl Cancer Inst       Date:  1970-01       Impact factor: 13.506

2.  Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism.

Authors:  J W Sixbey; Q Y Yao
Journal:  Science       Date:  1992-03-20       Impact factor: 47.728

3.  Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study.

Authors:  G de-Thé; A Geser; N E Day; P M Tukei; E H Williams; D P Beri; P G Smith; A G Dean; G W Bronkamm; P Feorino; W Henle
Journal:  Nature       Date:  1978-08-24       Impact factor: 49.962

4.  Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region.

Authors:  S J Lu; N E Day; L Degos; V Lepage; P C Wang; S H Chan; M Simons; B McKnight; D Easton; Y Zeng
Journal:  Nature       Date:  1990-08-02       Impact factor: 49.962

5.  Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): a multicenter follow-up study.

Authors:  F de-Vathaire; H Sancho-Garnier; H de-Thé; C Pieddeloup; G Schwaab; J H Ho; R Ellouz; C Micheau; M Cammoun; Y Cachin
Journal:  Int J Cancer       Date:  1988-08-15       Impact factor: 7.396

6.  EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx.

Authors:  H zur Hausen; H Schulte-Holthausen; G Klein; W Henle; G Henle; P Clifford; L Santesson
Journal:  Nature       Date:  1970-12-12       Impact factor: 49.962

Review 7.  Etiology of Burkitt's lymphoma--an alternative hypothesis to a vectored virus.

Authors:  D P Burkitt
Journal:  J Natl Cancer Inst       Date:  1969-01       Impact factor: 13.506

8.  [Esophageal cancer in Ille-et-Vilaine in relation to levels of alcohol and tobacco consumption. Risks are multiplying].

Authors:  A J Tuyns; G Péquignot; O M Jensen
Journal:  Bull Cancer       Date:  1977       Impact factor: 1.276

9.  Urinary excretion of nitrosamino acids and nitrate by inhabitants of high- and low-risk areas for nasopharyngeal carcinoma in southern China.

Authors:  Y Zeng; H Ohshima; G Bouvier; P Roy; J Zhong; B Li; I Brouet; G de Thé; H Bartsch
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1993 May-Jun       Impact factor: 4.254

10.  A comparison of Epstein-Barr virus-specific T-cell immunity in malaria-endemic and -nonendemic regions of Papua New Guinea.

Authors:  D J Moss; S R Burrows; D J Castelino; R G Kane; J H Pope; A B Rickinson; M P Alpers; P F Heywood
Journal:  Int J Cancer       Date:  1983-06-15       Impact factor: 7.396

View more
  2 in total

1.  Estimating avoidable causes of cancer.

Authors:  D L Davis; C Muir
Journal:  Environ Health Perspect       Date:  1995-11       Impact factor: 9.031

2.  Genetic factors leading to chronic Epstein-Barr virus infection and nasopharyngeal carcinoma in South East China: study design, methods and feasibility.

Authors:  Xiu Chan Guo; Kevin Scott; Yan Liu; Michael Dean; Victor David; George W Nelson; Randall C Johnson; Holli H Dilks; James Lautenberger; Bailey Kessing; Janice Martenson; Li Guan; Shan Sun; Hong Deng; Yuming Zheng; Guy de The; Jian Liao; Yi Zeng; Stephen J O'Brien; Cheryl A Winkler
Journal:  Hum Genomics       Date:  2006-06       Impact factor: 4.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.